Psoriasis is a skin condition that has affected millions and millions of people. In the United States alone, there are more than 7.5 million people who suffer from psoriasis, adding it to the list of the most common skin conditions in the world. Sufferers of psoriasis experience blisters on their skin in addition to flakiness, red patches, inflammation, and, many times, awfully painful scaly lesions. Most people over the world who suffer from this skin condition do not bother to seek help.
This is mainly because sufferers of psoriasis go through a series of bullying episodes during their lives and fall victim to the delusion they will be made fun of for seeking help as well. This is why the dermatologist who led the ixekizumab study, Dr. Craig Leonardi, said that the patients had to deal with stigma and often experienced psychological issues.
In 2012, researchers came across two different biological cures for the skin condition, brodalumab and ixekizumab, and medicated the sufferers by giving them injections that diminished interleukin-17, which is among the main culprits of the skin condition. Complete elimination of the lesions and terrible, patchy skin that the patients had developed was witnessed.
Scientists carried out studies to figure out which experimental therapy was better and showed positive results for the sufferers of plaque psoriasis. The study was focused around interleukin-17. Brodalumab and ixekizumab are the two experimental therapies, and they both focus on ridding the psoriasis sufferer of the disease by targeting interleukin-17. However, the two therapies work in different ways. The best way to differentiate the two is by understanding that brodalumab binds to the IL-17 receptor, which is neutralized by the ixekizumab.
One hundred ninety-eight patients of severe plaque psoriasis were treated with brodalumab in an attempt to see the effectiveness of the biological treatment. They were given moderate to heavy doses, either through injections or placebo. The results showed complete clear-up of the plaque psoriasis in 62 percent of the patients, whereas 75 percent of the patients experienced 90-percent removal of the painful lesions, patchy red skin, and flakiness.
To test the other experimental treatment, researchers treated around 142 patients with ixekizumab, which was given to the patients of plaque psoriasis in random doses. The results of the treatment were similar to those of the brodalumab study. Both studies showed the best results in patients who were given a heavier dosage than the rest. Only around two people in each of the studies’ conditions were rather stubborn, and it did not affect them as well as the treatments affected the other patients.